NCT00787384View on ClinicalTrials.gov

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Hypereosinophilic SyndromeChronic Eosinophilic LeukemiaChronic Idiopathic Hypereosinophilia
Interventions
DRUG

Imatinib

Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.

Trial Locations (4)

24128

USC Ematologia Ospedali Riuniti di Bergamo, Bergamo

36100

UO Ematologia, Azienda Ospedaliera ULSS6, Vicenza

50134

USC Ematologia Azienda Ospedaliera Università Careggi, Florence

Unknown

Divisione di Ematologia Spedali Civili di Brescia, Brescia

All Listed Sponsors
lead

Northern Italy Leukemia Group

OTHER

NCT00787384 - Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes | Biotech Hunter | Biotech Hunter